We have reported previously that R-enantiomer of etodolac (R-etodolac), which is under investigation in phase 2 clinical trials in chronic lymphocytic leukemia, induces potent cytotoxicity at clinically relevant concentrations in multiple myeloma (MM) cells. In this study, we demonstrated that SDX-308 (CEP-18082), a novel analog of etodolac, has more potent cytotoxicity than R-etodolac against both MM cell lines and patient MM cells, including tumor cells resistant to conventional (dexamethasone, doxorubicine, melphalan) and novel (bortezomib) therapies. SDX-308-induced cytotoxicity is triggered by caspase-8/9/3 activation and poly (ADP-ribose) polymerase cleavage, followed by apoptosis. SDX-308 significantly inhibits b-catenin/T-cell factor pathway by inhibiting nuclear translocation of b-catenin, thereby downregulating transcription and expression of downstream target proteins including myc and survivin. Neither interleukin-6 nor insulinlike growth factor-1 protect against growth inhibition triggered by SDX-308. Importantly, growth of MM cells adherent to bone marrow (BM) stromal cells is also significantly inhibited by SDX-308. Our data therefore indicate that the novel etodolac analog SDX-308 can target MM cells in the BM milieu.
Introduction
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits both cycloxygenase (COX)-1 and -2, and is FDA approved for the treatment of degenerative joint disease and rheumatoid arthritis. 1, 2 We recently reported that the R-enantiomer of etodolac (R-etodolac/SDX-101), a non-COX inhibitor currently under investigation in phase 2 clinical trials for treatment of refractory chronic lymphocytic leukemia (CLL), induces potent cytotoxicity at clinically relevant concentrations in conventional drug-sensitive and drug-resistant multiple myeloma (MM) cell lines, as well as in patient MM tumor cells.
3 SDX-308 (CEP-18082), a novel analog of etodolac, has more potent cytotoxicity than R-etodolac in several cancer cell lines including colon, prostate, ovarian and breast cancer, Recent studies have shown that NSAIDs including R-etodolac inhibit b-catenin-dependent transcription in malignant cells; however, its mechanisms of action has not yet been fully defined. [4] [5] [6] [7] Specifically, the colonic polyps of patients treated with NSAIDs have reduced nuclear accumulation of b-catenin. b-catenin/T-cell factor (TCF) signaling is known to regulate developmental processes and can lead to malignant transformation via upregulation of its target genes 8, 9 including c-myc, 10, 11 survivin, 12, 13 and cyclin D1 14 associated with MM cell growth and survival. Wnt inhibits GSK-3b activity and blocks b-catenin phosphorylation and its degradation in proteasomes. b-catenin accumulating in the cytoplasm then translocates to the nucleus binds to TCF4 complex, and activates transcription of target genes. 15 Recently, Derksen et al. 16 have demonstrated that MM cells overexpress b-catenin and that stimulation of b-catenin/ TCF pathway induces MM cell growth, suggesting that b-catenin/TCF pathway and its target genes represent a promising therapeutic target in MM. 17 In this report, we examined anti-MM activities of SDX-308 in both in vitro and ex vivo MM models. SDX-308 has more potent cytotoxicity than R-etodolac against MM cells, including conventional and novel drug-resistant MM cell lines and patient MM cells. It strongly inhibits b-catenin/TCF pathway, thereby downregulating downstream target proteins including myc and survivin.
Materials and methods
Detailed information pertinent to tumor cell lines and primary tumor specimens; 18 b-catenin/TCF transcriptional activity was measured using a b-catenin-dependent TCF reporter plasmid (TOPflash) luciferase reporter assay in HEK293 cells. The cells were co-transfected with the TOPflash reporter (Millipore Corporation, Billerica, MA, USA) containing TCF binding site and the b-catenin plasmid using FuGENE 6 Transfection Reagent (Roche Ltd, Basel, Switzerland). Cells were then treated with various concentrations of R-etodolac or SDX-308 for 4 h, and luciferase activity was measured using a Promega Steady-Glo luciferase assay system (Promega, Madison, WI, USA).
Results

SDX-308 induces cytotoxicity in MM cells
We first performed 48 50 of SDX-308 in these cells is significantly lower than that of R-etodolac. Moreover, SDX-308 induced dose-dependent cytotoxicity in CD138-positive tumor cells isolated from six patients whose MM was refractory to multiple prior therapies including dexamethasone, melphalan, thalidomide or bortezomib, with IC 50 values ranging from 14.5 to 52.8 mM (Figure 1b 
R-etodolac induces apoptosis via caspase-8/-9/-3 and PARP cleavage
The molecular mechanisms whereby SDX-308 triggers MM cell cytotoxicity were next delineated. Cell cycle profiling of MM.1S and RPMI8226 cells treated with SDX-308 at 4, 8 and 12 h revealed a significant increase in sub-G1 population in a timedependent fashion, suggesting apoptosis (Figure 2a and 2b, respectively). We next determined whether SDX-308-induced cytotoxicity is triggered by apoptosis using Apo 2.7 staining. Treatment of MM.1S and RPMI8226 cells with SDX-308 for 24 h significantly increases Apo 2.7-positive cells in a dose-dependent fashion (Figure 2c and d, respectively), confirming apoptotic cell death. The mechanism of SDX-308-induced apoptosis was studied by immunoblotting analysis. SDX-308 induces cleavage of caspase-8/-9/-3 and poly(ADP-ribose) polymerase (PARP) in MM1S and RPMI8226 cells in a doseand a time-dependent fashion (Figure 2e and f, respectively) . These results indicate that cytotoxicity triggered by SDX-308 is mediated via caspase-8/-9/-3 activation and apoptosis in MM cells.
SDX-308 inhibits b-catenin/TCF pathway
Since R-etodolac induces cytotoxicity associated with inhibition of b-catenin/TCF pathway in CLL cells, 6 we next examined whether SDX-308 inhibited this signaling pathway in MM cells. In a b-catenin-dependent TCF reporter assay in HEK293 cells, SDX-308 more potently inhibited this pathway than R-etodolac: IC 50 of SDX-308 was 46 mM, 10-fold lower than the IC 50 for Retodolac (683 mM) (Figure 3a) . We next investigated the mechanisms of b-catenin/TCF signaling inhibition by SDX-308. SDX-308 (12.5 or 25 mM) decreased nuclear b-catenin levels in both MM.1S and OPM1 cells (Figure 3b ), without affecting total b-catenin levels (Figure 3c ). These results indicated that SDX-308 downregulates baseline b-catenin nuclear translocation, thereby inhibiting b-catenin/TCF transcriptional activity in MM cells.
SDX-308 inhibits transcription and expression of b-catenin/TCF pathway downstream target genes
Since b-catenin/TCF pathway regulates downstream target genes such as myc 10, 11 and survivin, 12, 13 we next evaluated whether SDX-308 could inhibit transcription and protein expression of these gene products in MM cells. SDX-308 (12.5 or 25 mM) at 3 or 6 h significantly downregulated transcription of myc and survivin in MM.1S (Figure 4a ) and OPM1 cells (Figure 4b) , analyzed by quantative real-time PCR. Protein expression of myc and survivin was further assessed by immunoblotting. Consistent with real-time PCR data, SDX-308 (12.5 or 25 mM) at 6 or 12 h strongly downregulated protein levels of myc and survivin in MM.1S and OPM1 cells (Figure 4c (Figure 5b) , and SDX-308 inhibited this effect in a dose-dependent fashion. These data suggest that SDX-308 abrogates the growth stimulatory effect of the BM microenvironment on MM cells.
Discussion
Although MM is incurable with conventional and high-dose therapies, novel rationally based treatment strategies that target both MM cells as well as the BM microenvironment offer great promise to improve patient outcome [26] [27] [28] For example, thalidomide/Thalomide, 29 immunomodulatory derivative lenalidomide/Revlimid [30] [31] [32] and proteasome inhibitor bortezomib/ Velcade 33, 34 can overcome conventional drug resistance in both preclinical and clinical studies. 17, 26, 28, 35 In this report, we demonstrate that SDX-308, a novel analog of etodolac, induces cytotoxicity in dexamethasone-, doxorubicin-and melphalanresistant MM cell lines, in bortezomib-resistant lymphoma/ leukemia cells, as well as in patient MM cells, with IC 50 ranging from 14.5 to 52.8 mM, approximately 10-fold lower than the IC 50 Total cell lysates were subjected to immunoblotting using anticaspase-8, -9, and -3, PARP and a-tubulin Abs. Recently, attention has been focused on the antiproliferative activity of NSAIDs and their potential utility as chemopreventive and antitumor agents. 2, 36, 37 The long-term ingestion of various NSAIDs is associated with a reduced incidence of colorectal, 37 esophageal, 38 gastric, 39 prostate, lung and breast cancer. 2, 40 To date, however, the mechanisms underlying the effects of these drugs on cancer cells are not fully defined. 2 Although inhibition of COX with subsequent decrease in prostaglandin production may confer antitumor activity, these drugs also exert antiinflammatory and antitumor activity in COX-independent manners; 7,41 for example, NSAIDs inhibit several transcription and signaling cascades including nuclear factor kappa B [42] [43] [44] p42/44 MAPK, 45 and b-catenin/TCF. 4,5 2,5-Dimethyl-celecoxib, a COX-2 inhibitor celecoxib derivative lacking COX-2 activity, also has cytotoxic activity against prostate cancer 46 and MM. 47 Moreover, R-etodolac, an enantiomer of the NSAID etodolac lacking COX inhibitory activity, has cytotoxic activity against CLL, 6 prostate cancer 48, 49 and MM. 3, 50 In this study, we demonstrated that the novel etodolac derivative SDX-308 inhibits b-catenin/TCF pathway and induces MM cytotoxicity, without significant COX inhibition. As side effects related to inhibition of COX-1 (gastrointestinal and renal toxicity) and COX-2 (cardiovascular toxicity) can be dose limiting, the strategy to develop and use COX-independent NSAID derivatives like SDX-308 as cancer chemopreventive and chemotherapeutic agents is promising.
Activation of the multifunctional protein b-catenin plays a critical role in the development of colorectal, 5, [13] [14] [15] prostate, 51 and breast cancer. 52 Accumulated b-catenin translocates to the nucleus and binds with TCF4 to regulate its target genes 8, 9 including myc, 10,11 survivin 12,13 and cyclin D1, 14 associated with neoplastic transformation and in MM growth and survival. MM cells overexpress b-catenin, consistent with active b-catenin/TCF-mediated transcription, but do not have detectable mutations in Wnt signaling such as APC and b-catenin. 16 Further activation of b-catenin/TCF pathway with either Wnt3a or the constitutively active S33Y mutant of b-catenin induces MM cell proliferation, 16 suggesting b-catenin as a therapeutic target in MM. In this study, we demonstrated that SDX-308 inhibits b-catenin/TCF pathway and downregulates its target molecules myc and survivin, as well as induces cytotoxicity and apoptosis in two different MM cell lines. Importantly, SDX-308 induces cytotoxicity in bortezomib-resistant DHL4 and KG-1 tumor cells. Our prior gene expression profiling of B-cell lymphoma cells resistant and sensitive to bortezomib revealed that overexpression of TCF4 is associated with bortezomib resistance; 53 conversely, inhibition of b-catenin nuclear locali- zation triggered by SDX-308 can, at least partially, overcome bortezomib resistance in these cells.
We and others have previously reported that IL-6 triggers MM cell proliferation and survival via activation of the Ras/Raf/ mitogen-activated protein kinase (MAPK) kinase/ p42/44 MAPK, 54 phosphatidylinositol 3-kinase (PI3-K)/Akt 55 and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling cascades. 56 IGF-1 also promotes MM cell proliferation and survival via Ras/Raf/MAPK kinase/p42/44 MAPK and PI3-K/Akt signaling cascades. 22 Our results suggest that neither IL-6 nor IGF-1 protect against SDX-308-induced cytotoxicity. As BMSCs confer growth stimulation and drug resistance effects in MM cells in the BM milieu, [23] [24] [25] we further studied the effect of SDX-308 on MM cells in the BM microenvironment. R-etodolac inhibits thymidine incorporation even of MM.1S adherent to BMSCs, indicating that SDX-308, in contrast to conventional therapies, can overcome tumor cell adhesion mediated drug resistance in the BM microenvironment.
In summary, the novel etodolac analog SDX-308 has more cytotoxicity than R-etodolac in MM cells. It inhibits b-catenin/ TCF pathway and induces apoptosis in drug-sensitive and drugresistant MM cell lines and patient MM cells within the BM milieu at concentrations without cytotoxicity to normal cells including PBMCs and BMMCs.
